亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Canine Erythropoietin Gene and Recombinant Protein

詳細技術說明
Anemia, a condition in which too few red blood cells (RBCs) are in circulation is characterized by clinical signs of weakness, lethargy and inappetance and can be divided into two forms - regenerative and nonregenerative
*Abstract

Anemia, a condition in which too few red blood cells (RBCs) are in circulation is characterized by clinical signs of weakness, lethargy and inappetance and can be divided into two forms - regenerative and nonregenerative. In regenerative anemia, the bone marrow continuously produces RBCs in response to blood loss (eg, during surgery or trauma) or destruction of RBCs by the immune system. In nonregenerative anemia, the bone marrow cannot or does not respond to the anemia. Its potential causes include, among other chronic diseases, chronic renal failure (CRF) and cancer.

Human erythropioietin (hEPO), a glycosylated protein that stimulates RBC production is commercially available to treat nonregenerative anemia caused by CRF and cancer, with global annual sales exceeding $10 billion dollars. However, CRF and other chronic diseases that cause milder forms of nonregenerative anemia are also significant problems in canines.

Without commercially available canine EPO (cEPO), veterinarians must weigh potential benefit of hEPO treatment against serious potential risk in canines - the development of neutralizing antibodies, which render therapy ineffective and potentially cross-neutralize endogenous EPO, which can cause a life threatening condition called red cell aplasia.

The current invention has identified the cEPO gene and describes the increased safety and efficacy of recombinant cEPO in the treatment of nonregenerative anemia in dogs.

Advantages
  • Increased safety and efficacy in the treatment of nonregenerative anemia in canines
  • High recombinant cEPO protein expression system in Chinese Hamster Ovary (CHO) cells

    See also D-2778: Feline Erythropoietin Expression System

    •
    *Licensing
    Phillip Owh, Senior Technology Commercialization and Liaison Officerpo62@cornell.edu607-254-4508
    其他
    MacLeod JN et al. Expression and bioactivity of recombinant canine erythropoietin. Am J Vet Res. 1998 Sep;59(9):1144-8.

    http://www.ncbi.nlm.nih.gov/pubmed/9736393?ordinalpos=18&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

    Randolph JE et al. Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. J Vet Intern Med. 2004 Jan-Feb;18(1):81-91.

    http://www.ncbi.nlm.nih.gov/pubmed/14765736?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

    Randolph JF et al. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am J Vet Res. 1999 May;60(5):636-42.

    http://www.ncbi.nlm.nih.gov/pubmed/10328437?ordinalpos=17&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
    國家/地區
    美國

    欲了解更多信息，請點擊 這裡
    移動設備